The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence

@article{Mason2010TheNC,
  title={The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence},
  author={B. Mason and C. Heyser},
  journal={Expert Opinion on Drug Safety},
  year={2010},
  volume={9},
  pages={177 - 188}
}
Importance to the field: Acamprosate, marketed under the brand name Campral®, (Forest Pharmaceuticals, Inc., Saint Louis, MO, USA; Merck Sante s.a.s., Lyon, France) is an orally administered drug approved in the US and throughout much of the world for treating alcohol dependence. Its safety and efficacy have been demonstrated in a number of clinical trials worldwide and as with all pharmacotherapies for alcoholism, it is used in conjunction with psychosocial interventions. Areas covered in this… Expand
The development of acamprosate as a treatment against alcohol relapse
TLDR
Future research on acamprosate or newer pharmacotherapeutics should consider assessing plasma and/or brain levels of calcium as a correlate or mediating factor in anti-relapse efficacy. Expand
The clinical pharmacology of acamprosate
TLDR
Although acamprosate has been called an anticraving drug, its subjective effects are subtle and relate to diminished arousal, anxiety and insomnia, which parallel preclinical findings of decreased withdrawal symptoms in animals treated with acamposate. Expand
Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
TLDR
Acamprosate has demonstrated its efficacy in more than 25 placebo-controlled, double-blind trials for individuals with alcohol dependence, and has generally been found to be more efficacious than placebo in significantly reducing the risk of returning to any drinking and increasing the cumulative duration of abstinence. Expand
Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence
TLDR
Current clinical data on the safety, efficacy, and pharmacokinetic properties of acamprosate, as well as theories on its potential mechanism of action are summarized and a discussion of the place of acamrosate in addiction medicine and therapy is discussed. Expand
Alcohol addiction - the safety of available approved treatment options
TLDR
All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease, but for some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function. Expand
Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
TLDR
Acamprosate was not more effective than placebo in reducing drinking or symptoms of schizophrenia, but it can be safely used in patients with alcohol dependence and comorbid schizophrenia spectrum disorders. Expand
Effects of Acamprosate on Cognition in a Treatment Study of Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
TLDR
The results showed that acamprosate had no effect on cognitive functioning and that there was no relationship between change in alcohol consumption or psychotic symptoms and change in cognitive functioning in this sample of patients. Expand
Alcohol Craving, Glutamate and Acamprosate
TLDR
Recent developments in the pharmacotherapy of alcohol dependence have targeted the phenomenon of craving in order to improve abstinence rates, and the role of pharmacotherapy in relapse prevention has become increasingly evident. Expand
Evolución de pacientes con adicción al alcohol con el uso de acamprosato
TLDR
The treatment with acamprosate is effective for the prevention of relapses and the reduction of alcohol dependence and agrees with other international study on this drug. Expand
PRECLINICAL INVESTIGATIONS OF GLYT-1 INHIBITION AS A NEW CONCEPT FOR TREATMENT OF ALCOHOL DEPENDENCE
Alcohol addiction and abuse is a main contributor to the global burden of disease and is a high public health priority. Alcohol addiction is a chronically relapsing neurobiological disorder affectingExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 138 REFERENCES
Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.
  • B. Mason
  • Medicine
  • The Journal of clinical psychiatry
  • 2001
TLDR
The drug's reliable effect on prolonging abstinence, in conjunction with an excellent safety profile, suggests that acamprosate may be useful for a broad range of patients with alcohol dependence. Expand
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
  • B. Mason
  • Medicine
  • Journal of studies on alcohol. Supplement
  • 2005
TLDR
These factors support investigating the efficacy and safety of combining acamprosate and naltrexone for the treatment of alcohol dependence in a large-scale multisite trial, with evaluation of potential predictors of response to each drug alone and in combination relative to placebo. Expand
Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.
TLDR
Oral acamprosate, as an adjunct to psychosocial/behavioural therapies, represents a novel advance for the management of alcohol-dependent patients in the postdetoxification period and appears to be dose dependent and enhanced by the addition of disulfiram. Expand
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
TLDR
Both naltrexone and acamprosate are efficacious in reducing alcohol consumption in alcoholics, however, their specific role in alcoholism treatment remains to be more clearly defined. Expand
Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting.
TLDR
Acamprosate seems to be an effective treatment for alcohol dependence in a Brazilian population according to the results of a double-blind, placebo-controlled, 24-week study carried out at the University of São Paulo, Brazil. Expand
Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.
TLDR
The US study findings suggest that acamprosate is safe and well tolerated in a broadly inclusive sample of alcoholics and appears effective in populations of patients motivated to have a treatment goal of abstinence. Expand
Acamprosate in the treatment of alcoholism: mechanisms and perspectives
TLDR
Studies in which acamprosate was given in combination with disulfiram or naltrexone also showed promising results, and further studies are underway to identify potential acamrosate responders on a neurobiological basis to improve its efficacy and cost–effectiveness. Expand
Acamprosate in the treatment of alcohol dependence
  • B. Mason
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2005
TLDR
Patients treated with acamprosate achieve greater rates of complete abstinence, longer times to first drink and/or increased duration of cumulative abstinence when compared with placebo. Expand
Acamprosate in Alcohol Dependence: Implications of a Unique Mechanism of Action
TLDR
Research suggests that acamprosate may modulate NMDA receptors via regulatory polyamine sites, or that it may act directly on metabotropic glutamate receptors, both of which are novel for the treatment of alcohol dependence. Expand
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
TLDR
Both acamprosate and naltrexone are effective as adjuvant therapies for alcohol dependence in adults and both drugs are safe and acceptably tolerated but issues of compliance need to be addressed adequately to assure their usefulness in clinical practice. Expand
...
1
2
3
4
5
...